Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics

 Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics

Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics

Shots:

  • Pear Therapeutics will solely be responsible for commercialization of its prescription digital therapeutics (PDTs), reSET and reSET-O, therapies to treat substance use disorder (SUD) and opioid use disorder (OUD) respectively
  • In Apr’2018, the companies collaborated to develop and commercialize PDTs. The termination of prescription app deal is a part of Sandoz transformation and subsequent leadership change resulted in a reinforced focus on and capital allocation for Sandoz’s core business
  • Sandoz will continue to partner with Pear and support the commercial efforts through a transition period to ensure patients access to reSET and reSET-O. reSET is a 90-days PDT intended to provide CBT while reSET-O is an 84-days PDT intended to increase retention of patients in outpatient treatment by CBT

Click here to­ read full press release/ article | Ref: Sandoz| Image: Pear Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post